PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
Go back to PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 14.70 -0.35 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.05 | 52 Week High | $19.40 | |||
| Open | $15.05 | 52 Week Low | $12.50 | |||
| Day High | $15.40 | P/E | N/A | |||
| Day Low | $14.67 | EPS | $0.00 | |||
| Volume | 47,252 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.00 -0.45 (1.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.45 | 52 Week High | $37.39 | |||
| Open | $28.02 | 52 Week Low | $28.25 | |||
| Day High | $28.15 | P/E | 16.97 | |||
| Day Low | $27.72 | EPS | $1.65 | |||
| Volume | 14,635,657 | |||||
